Effectiveness and Safety of Sarilumab in Polymyalgia Rheumatica: a retrospective study of the FIRST Registry
These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.
Authors
- Yusuke Miyazaki (ORCID: https://orcid.org/0000-0001-5692-3881)
- Yoshino Inoue
- Takafumi Aritomi
- Naoaki Ohkubo (ORCID: https://orcid.org/0000-0003-2265-4104)
- Ippei Miyagawa (ORCID: https://orcid.org/0000-0002-9071-145X)
- Atsushi Nagayasu (ORCID: https://orcid.org/0000-0002-0383-1091)
- Shingo Nakayamada (ORCID: https://orcid.org/0000-0002-2209-8454)
- Koshiro Sonomoto (ORCID: https://orcid.org/0000-0002-4003-8842)
- Kazuki Takahashi (ORCID: https://orcid.org/0000-0001-5924-1376)
- Ryuichiro Kanda (ORCID: https://orcid.org/0000-0001-8247-6595)
- Hidenori Sakai
- Yurie Satoh-Kanda
- Mayu Nishimoto
- Yoshiya Tanaka
- Masashi Funada
- Satoshi Kubo
- Yuya Fujita
- Hiroaki Tanaka
- Masanobu Ueno
- Kiyotake Yoshioka
Institutions
- University of Occupational and Environmental Health Japan (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1093/mr/roag030
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00